Current and Future Therapeutics for Treating Patients with Sickle Cell Disease
M Barak, C Hu, A Matthews, YM Fortenberry - Cells, 2024 - mdpi.com
Sickle cell disease (SCD) is the most common genetic blood disorder in the United States,
with over 100,000 people suffering from this debilitating disease. SCD is caused by …
with over 100,000 people suffering from this debilitating disease. SCD is caused by …
Current and emerging drug treatment strategies to tackle sickle cell anemia
Y Persaud, A Leonard, P Rai - Expert Opinion on Emerging Drugs, 2024 - Taylor & Francis
Introduction Since its discovery in the early 1900s, sickle cell disease (SCD) has contributed
significantly to the scientific understanding of hemoglobin and hemoglobinopathies. Despite …
significantly to the scientific understanding of hemoglobin and hemoglobinopathies. Despite …
Study protocol for ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness): Using small business partnerships to deliver a scalable and …
J Walden, L Brown, S Seiguer, K Munshaw, J Rausch… - PloS one, 2024 - journals.plos.org
Sickle cell disease (SCD) is an inherited blood disorder that affects approximately 100,000
Americans, primarily from underrepresented racial minority populations, and results in …
Americans, primarily from underrepresented racial minority populations, and results in …
Activating pyruvate kinase improves red blood cell integrity by reducing band 3 tyrosine phosphorylation
K Le, X Wang, J Chu, M Lundt, YY Lee… - Blood …, 2024 - ashpublications.org
In a Phase 1 study (NCT04000165), we established proof-of-concept for activating pyruvate
kinase (PK) in sickle cell disease (SCD) as a viable anti-sickling therapy. AG-348 (mitapivat) …
kinase (PK) in sickle cell disease (SCD) as a viable anti-sickling therapy. AG-348 (mitapivat) …
[HTML][HTML] Exciting science from the 16th International Conference on Thalassemia and Hemoglobinopathies
D Farmakis, M Angastiniotis, A Eleftheriou - HemaSphere, 2024 - ncbi.nlm.nih.gov
The 16th International Conference on Thalassemia & Hemoglobinopathies was held
together with the 18th International Conference for Patients and Parents in Kuala Lumpur …
together with the 18th International Conference for Patients and Parents in Kuala Lumpur …
Progress And Challenges In Africa At The Time Of Molecular Haematology
L Luzzatto - Nigerian Journal of Haematology, 2023 - njhaem.org.ng
The study of blood diseases has been traditionally at the border between clinical medicine
and laboratory science. Many of us have been attracted to haematology by this combination …
and laboratory science. Many of us have been attracted to haematology by this combination …